CNBC on MSN23d
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions – NBC Los Angeles
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
Business Insider22d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
Earlier in December, telehealth company Ro announced a partnership with Eli Lilly to offer a half-price version of Zepbound, Lilly's brand-name tirzepatide product. The cheaper option is sold in ...
USA Today27d
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Now that the FDA has decided tirzepatide is no longer in shortage ... Consumers and elected officials have raised concerns about the prices of brand-name glucagon-like peptide 1, or GLP-1.
Citi downgrades Hims & Hers to Sell on valuation concerns
Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...